Predictors of Intracranial Hemorrhage Volume Expansion in Patients Receiving Factor Xa Inhibitors in ANNEXA‐4: Time and Severity Matter Most

Background Andexanet alfa, a specific reversal agent for factor Xa inhibitors, resulted in effective hemostasis in 79% of patients with intracranial bleeding in the ANNEXA‐4 (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of Factor Xa Inhibitors) trial (NCT02329327). However, little...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Mauricio Concha, Lizhen Xu, MacKenzie Horn, Tomoyuki Ohara, Juliet Nakamya, Jan Beyer‐Westendorf, Ashkan Shoamanesh, Alexander Cohen, Per Ladenvall, Stuart J. Connolly, Andrew M. Demchuk
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Wolters Kluwer Health 2024-01-01
Ráidu:	Stroke: Vascular and Interventional Neurology
Fáttát:	andexanet alfa anti‐factor Xa activity direct factor Xa inhibitor reversal hematoma expansion intracranial hemorrhage
Liŋkkat:	https://www.ahajournals.org/doi/10.1161/SVIN.123.000997
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!